SCHEMBL3724640

SCHEMBL3724640

O=S(=O)(On1nnc2ccc(Cl)cc21)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.47
ALDH1A1 P00352 4/20 0.47
HPGD P15428 2/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
CYP2C19 P33261 2/20 0.44
TSHR P16473 2/20 0.42
CASP3 P42574 2/20 0.42
SENP8 Q96LD8 2/20 0.42
SENP7 Q9BQF6 2/20 0.42
SENP6 Q9GZR1 2/20 0.42
KMO O15229 1/20 0.42
SLC9A1 P19634 2/20 0.41
CRHBP P24387 1/20 0.40
RECQL P46063 1/20 0.40
CRHR2 Q13324 1/20 0.40
POLB P06746 1/20 0.39
PARL Q9H300 1/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL417797 0.92 KMT2A (0.48) SMN1; SMN2ALDH1A1HPGDKMT2AMEN1
SCHEMBL7383122 0.87 KMT2A (0.45) SMN1; SMN2ALDH1A1HPGDKMT2AMEN1
SCHEMBL7114768 0.84 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1HPGDKMT2AMEN1
SCHEMBL9817222 0.83 CYP2C19 (0.59) SMN1; SMN2ALDH1A1HPGDKMT2ATDP1
SCHEMBL2803342 0.83 SLC9A1 (0.55) SMN1; SMN2ALDH1A1HPGDKMT2ACYP2C19
SCHEMBL11458575 0.81 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1HPGDKMT2AMEN1
SCHEMBL11450733 0.80 KMT2A (0.50) SMN1; SMN2ALDH1A1HPGDKMT2AMEN1
SCHEMBL27695892 0.80 TDP1 (0.40) SMN1; SMN2ALDH1A1HPGDKMT2AMEN1
SCHEMBL11456500 0.80 KMT2A (0.46) SMN1; SMN2ALDH1A1HPGDKMT2AMEN1
SCHEMBL11450688 0.79 CYP2C19 (0.40) SMN1; SMN2ALDH1A1HPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF INSTITUT CURIE (FR) 2026-05-21 US disclosed
US-12527854-B2 Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof INSTITUT CURIE (FR) 2026-01-20 US disclosed
US-20220233673-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF INSTITUT CURIE (FR) 2022-07-28 US disclosed
EP-2106263-B1 WATER SOLUBLE REACTIVE DERIVATIVES OF CARBOXY POLYSACCHARIDES AND FIBRINOGEN CONJUGATES THEREOF HEPACORE LTD (IL) 2016-12-21 EP disclosed
US-20130084278-A1 WATER SOLUBLE REACTIVE DERIVATIVES OF CARBOXY POLYSACCHARIDES AND FIBRINOGEN CONJUGATES THEREOF HEPACORE LTD. (IL) 2013-04-04 US disclosed
US-8329870-B2 Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof HEPACORE LTD. (IL) 2012-12-11 US disclosed
US-20100086594-A1 WATER SOLUBLE REACTIVE DERIVATIVES OF CARBOXY POLYSACCHARIDES AND FIBRINOGEN CONJUGATES THEREOF HEPACORE LTD. (IL) 2010-04-08 US disclosed
EP-2106263-A2 WATER SOLUBLE REACTIVE DERIVATIVES OF CARBOXY POLYSACCHARIDES AND FIBRINOGEN CONJUGATES THEREOF Hepacore Ltd. (IL) 2009-10-07 EP disclosed
WO-2008081463-A2 WATER SOLUBLE REACTIVE DERIVATIVES OF CARBOXY POLYSACCHARIDES AND FIBRINOGEN CONJUGATES THEREOF HEPACORE LTD. (IL) 2008-07-10 WO disclosed
US-RE32992-E THERAPY FOR INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS Fujisawa Pharaceutical Co., Ltd. (JP) 1989-07-18 US disclosed
US-4427581-A BACTERICIDES, FUNGICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-01-24 US disclosed
EP-0088386-A1 New 1,4-diaminocyclitol derivatives, processes for their preparation and pharmaceutical compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-09-14 EP disclosed
US-4354966-A Peptides, process for preparation thereof and use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-10-19 US disclosed
EP-0057412-A1 Peptide, process for preparation thereof and use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-08-11 EP disclosed
US-4311640-A ANTIBIOTIC FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-01-19 US disclosed
EP-0027260-A2 Peptides, processes for their preparation and pharmaceutical compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-04-22 EP disclosed
EP-0025842-A2 Peptides, process for their preparation, their pharmaceutical compositions and their intermediates FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-04-01 EP disclosed
US-4242507-A Sulfonic acid esters FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-12-30 US disclosed
US-4206156-A ANTIMICROBIAL FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) 1980-06-03 US disclosed
US-4182758-A BACTERICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527854-B2 Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof STXBP1, RNGTT, UPF1 SMN1; SMN2 431/4885ALDH1A1 4838/4885HPGD 4708/4885
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF STXBP1, HBB, UPF1 SMN1; SMN2 526/4885ALDH1A1 4710/4885HPGD 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.